Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986883 | 0.90 | PNP (0.34) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL26189597 | 0.80 | PNP (0.46) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL26233431 | 0.80 | PNP (0.47) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23710630 | 0.78 | HPGD (0.52) | LMNATP53HIF1ANT5E | |
| SCHEMBL31685677 | 0.75 | PNP (0.55) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL19662722 | 0.74 | POLA1 (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL22571146 | 0.74 | POLA1 (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23734167 | 0.74 | POLA1 (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL29455222 | 0.74 | POLA1 (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL17521209 | 0.74 | PNP (0.58) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247540-B2 | Caged nucleotides and oligonucleotides and their application | DEITERS ALEXANDER (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100099159-A1 | CAGED NUCLEOTIDES AND OLIGONUCLEOTIDES AND THEIR APPLICATION | DEITERS ALEXANDER | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099159-A1 | CAGED NUCLEOTIDES AND OLIGONUCLEOTIDES AND THEIR APPLICATION | RNGTT, NT5C3B, ADAR | PNP 19/4885LMNA 878/4885TP53 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.